6Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996; 271: 18295-8.
7Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996; 16: 921-32.
8Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castafio EM,Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4: 822-6.
9Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ,Calderon FH, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998; 18: 3213-23.
10Geula C, Mesulam M. Special properties of cholinesterase in the cerebral cortex of Alzheimer's disease. Brain Res 1989;498:185-9
8Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]. Control Clin Trials, 1996,17( 1 ) : 1.
9Moher D, Pham B, Jones A, et al.Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta-analysis[J]. Lancet, 1998, 352 (9 128) : 609.
